Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 24492474)

1.

Inhibition of NOX/VPO1 pathway and inflammatory reaction by trimethoxystilbene in prevention of cardiovascular remodeling in hypoxia-induced pulmonary hypertensive rats.

Liu B, Luo XJ, Yang ZB, Zhang JJ, Li TB, Zhang XJ, Ma QL, Zhang GG, Hu CP, Peng J.

J Cardiovasc Pharmacol. 2014 Jun;63(6):567-76. doi: 10.1097/FJC.0000000000000082.

PMID:
24492474
2.

Targeting mitochondrial reactive oxygen species to modulate hypoxia-induced pulmonary hypertension.

Adesina SE, Kang BY, Bijli KM, Ma J, Cheng J, Murphy T, Michael Hart C, Sutliff RL.

Free Radic Biol Med. 2015 Jun 11. pii: S0891-5849(15)00265-8. doi: 10.1016/j.freeradbiomed.2015.05.042. [Epub ahead of print]

PMID:
26073127
3.

Mammalian target of rapamycin overexpression antagonizes chronic hypoxia-triggered pulmonary arterial hypertension via the autophagic pathway.

Li L, Wang X, Wang L, Qu L, Zhu X, Li M, Dang X, Li P, Gao Y, Peng Z, Pan L, Wan L.

Int J Mol Med. 2015 Jul;36(1):316-22. doi: 10.3892/ijmm.2015.2224. Epub 2015 May 26.

PMID:
26017061
4.

Stem and progenitor cell therapy for pulmonary arterial hypertension: effects on the right ventricle (2013 Grover Conference Series).

van der Laarse A, Cobbaert CM, Umar S.

Pulm Circ. 2015 Mar;5(1):73-80. doi: 10.1086/679701. Review.

5.

Wnt5a attenuates hypoxia-induced pulmonary arteriolar remodeling and right ventricular hypertrophy in mice.

Jin Y, Wang W, Chai S, Liu J, Yang T, Wang J.

Exp Biol Med (Maywood). 2015 May 7. pii: 1535370215584889. [Epub ahead of print]

PMID:
25956683
6.

Iptakalim attenuates hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection.

Zhu R, Bi LQ, Wu SL, Li L, Kong H, Xie WP, Wang H, Meng ZL.

Mol Med Rep. 2015 Aug;12(2):2945-52. doi: 10.3892/mmr.2015.3695. Epub 2015 Apr 28.

PMID:
25936382
7.

MicroRNA-145-targeted drug and its preventive effect on pulmonary arterial hypertension (patent WO2012153135 A1).

Ogorodnikova N, Arenz C.

Expert Opin Ther Pat. 2015 Jun;25(6):723-7. doi: 10.1517/13543776.2015.1025751. Epub 2015 Mar 18.

PMID:
25787302
8.

Increased eicosanoid levels in the Sugen/chronic hypoxia model of severe pulmonary hypertension.

Al-Husseini A, Wijesinghe DS, Farkas L, Kraskauskas D, Drake JI, Van Tassel B, Abbate A, Chalfant CE, Voelkel NF.

PLoS One. 2015 Mar 18;10(3):e0120157. doi: 10.1371/journal.pone.0120157. eCollection 2015.

9.

Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension.

Liles JT, Hoyer K, Oliver J, Chi L, Dhalla AK, Belardinelli L.

J Pharmacol Exp Ther. 2015 Jun;353(3):480-9. doi: 10.1124/jpet.114.221861. Epub 2015 Mar 13.

PMID:
25770134
10.

Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat.

Cotroneo E, Ashek A, Wang L, Wharton J, Dubois O, Bozorgi S, Busbridge M, Alavian KN, Wilkins MR, Zhao L.

Circ Res. 2015 May 8;116(10):1680-90. doi: 10.1161/CIRCRESAHA.116.305265. Epub 2015 Mar 12.

PMID:
25767292
11.
12.

Adventitial alterations are the main features in pulmonary artery remodeling due to long-term chronic intermittent hypobaric hypoxia in rats.

Brito J, Siques P, Arribas SM, López de Pablo AL, González MC, Naveas N, Arriaza K, Flores K, León-Velarde F, Pulido R, Ordenes S, López MR.

Biomed Res Int. 2015;2015:169841. doi: 10.1155/2015/169841. Epub 2015 Feb 8.

13.

Effects of chrysin (5,7-dihydroxyflavone) on vascular remodeling in hypoxia-induced pulmonary hypertension in rats.

Li XW, Wang XM, Li S, Yang JR.

Chin Med. 2015 Feb 18;10:4. doi: 10.1186/s13020-015-0032-2. eCollection 2015.

14.

Effect of thoracic epidural blockade on hypoxia-induced pulmonary arterial hypertension in rats.

Yu SH, Chen JY, Zhang YM, Jiao GW, Liu FQ, Kong LF.

Iran J Basic Med Sci. 2014 Sep;17(9):710-5.

15.

Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration.

Irwin DC, Baek JH, Hassell K, Nuss R, Eigenberger P, Lisk C, Loomis Z, Maltzahn J, Stenmark KR, Nozik-Grayck E, Buehler PW.

Free Radic Biol Med. 2015 May;82:50-62. doi: 10.1016/j.freeradbiomed.2015.01.012. Epub 2015 Feb 2.

PMID:
25656991
16.

Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.

Lan B, Hayama E, Kawaguchi N, Furutani Y, Nakanishi T.

PLoS One. 2015 Jan 28;10(1):e0117211. doi: 10.1371/journal.pone.0117211. eCollection 2015.

17.

Early detection of pulmonary arterial hypertension: do not forget the right ventricle.

Ruocco G, Palazzuoli A.

Nat Rev Cardiol. 2015 Mar;12(3):134. doi: 10.1038/nrcardio.2014.191-c1. Epub 2015 Jan 13. No abstract available.

PMID:
25583621
18.

More on the right ventricle in pulmonary hypertension.

Naeije R, Ghio S.

Eur Respir J. 2015 Jan;45(1):33-5. doi: 10.1183/09031936.00209414. No abstract available.

PMID:
25552736
19.

Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats.

Tang B, Chen GX, Liang MY, Yao JP, Wu ZK.

Int J Cardiol. 2015 Feb 1;180:134-41. doi: 10.1016/j.ijcard.2014.11.161. Epub 2014 Nov 25.

20.

miR-29a-3p attenuates hypoxic pulmonary hypertension by inhibiting pulmonary adventitial fibroblast activation.

Luo Y, Dong HY, Zhang B, Feng Z, Liu Y, Gao YQ, Dong MQ, Li ZC.

Hypertension. 2015 Feb;65(2):414-20. doi: 10.1161/HYPERTENSIONAHA.114.04600. Epub 2014 Nov 24.

PMID:
25421979
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk